Cargo Therapeutics Inc. (CRGX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
CRGX Chart
CARGO Therapeutics Provides Corporate Update
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).
An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Cargo Therapeutics Inc. Dividends
Cargo Therapeutics Inc. Earnings
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 21 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 14 May 2025 Date | | - Cons. EPS | - EPS |
| 21 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
Cargo Therapeutics Inc. (CRGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cargo Therapeutics Inc. ever had a stock split?
Cargo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Anup Radhakrishnan CEO | NASDAQ (NGS) Exchange | 14179K101 Cusip |
| US Country | 167 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CARGO Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing novel chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Originally established as Syncopation Life Sciences, Inc., the company underwent a rebranding in September 2022, adopting the name CARGO Therapeutics, Inc. to reflect its focused mission. Founded in 2019, CARGO Therapeutics has quickly positioned itself in the forefront of CAR T-cell therapy innovation, operating from its headquarters in San Mateo, California. Its commitment to addressing the challenges of cancer treatment through cutting-edge cellular immunotherapies showcases its pioneering spirit in the biotechnological arena.
Products and Services
CRG-022: CRG-022 stands as CARGO Therapeutics, Inc.'s premier product candidate, marking a significant stride in the field of CAR T-cell therapy. This autologous CD22 CAR T-cell product is meticulously designed to combat the mechanisms underlying resistance in cancer therapy. By targeting CD22, an alternate tumor antigen prevalent in B-cell malignancies, CRG-022 distinguishes itself as a promising therapeutic option that seeks to improve outcomes for patients facing these challenging cancers.
CRG-023: Advancing its innovative portfolio, CARGO Therapeutics, Inc. also dedicates resources to the development of CRG-023, a tri-specific CAR T product candidate. This ambitious therapeutic approach ingeniously targets tumor cells by recognizing three B-cell antigen targets simultaneously. The pioneering nature of CRG-023 exemplifies the company’s commitment to pushing the boundaries of CAR T-cell therapy, aiming to provide a more comprehensive and potentially more effective treatment solution for cancer patients.
Contact Information
